MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4

Background Aim to determine the clinicopathological and prognostic role of miR-301a-3p in pancreatic ductal adenocarcinoma(PDAC), to investigate the biological mechanism of miR-301a-3p in vitro and in vivo. Methods By tissue microarray analysis, we studied miR-301a-3p expression in PDAC patients and its clinicopathological correlations as well as prognostic significance. qRT-PCR was used to test miR-301a-3p expression in PDAC tissues and cell lines. Functional experiments including in vitro and in vivo were performed. Results Significantly higher expression of miR-301a-3p were found in PDAC patients with lymph node metastasis and advanced pathological stages and identified as an independent prognostic factor for worse survival. In PDAC samples and cell lines, miR-301a-3p was significantly up-regulated compared with matched non-tumor tissues and normal pancreatic ductal cells, respectively. Overexpression of miR-301a-3p enhanced PDAC cells colony, invasion and migration abilities in vitro as well as tumorigenicity in vivo. Furthermore, SMAD4 was identified as a target gene of miR-301a-3p by cell as well as mice xenograft experiments. In PDAC tissue microarray, a significantly inverse correlation between miR-301a-3p ISH scores and SMAD4 IHC scores were observed in both tumor and corresponding non-tumor tissues. Conclusion MiR-301a-3p functions as a novel oncogene in PDAC and the oncogenic activity may involve its inhibition of the target gene SMAD4.

[1]  Yong Li,et al.  MicroRNAs in NF-kappaB signaling. , 2011, Journal of molecular cell biology.

[2]  Na Li,et al.  Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. , 2011, Oncology reports.

[3]  S. Shenouda,et al.  MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.

[4]  Z. Ye,et al.  Abnormal expression of miR‐301a in gastric cancer associated with progression and poor prognosis , 2013, Journal of surgical oncology.

[5]  Yonghong Xiao,et al.  microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. , 2012, Cancer discovery.

[6]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[7]  F. Slack,et al.  MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications , 2013, Genome Medicine.

[8]  M. Moore,et al.  Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.

[9]  Michael K. Wendt,et al.  Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression , 2011, Cell and Tissue Research.

[10]  R. Srinivasan,et al.  SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2012, Pancreas.

[11]  C. Hill,et al.  Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. , 2005, Molecular and cellular biology.

[12]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[13]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[14]  T. Tuschl,et al.  Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.

[15]  Giovanni Parmigiani,et al.  SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer , 2009, Clinical Cancer Research.

[16]  D. Wazer,et al.  Adjuvant therapy for pancreatic cancer. , 2014, JOP : Journal of the pancreas.

[17]  Anthony Fyles,et al.  MicroRNA-301 mediates proliferation and invasion in human breast cancer. , 2011, Cancer research.

[18]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[19]  Cheng‐Yi Chen,et al.  MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. , 2014, Cancer letters.

[20]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[21]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[22]  J. Neoptolemos,et al.  Adjuvant Therapy in Pancreatic Cancer , 2015 .

[23]  K. Venkatasubbarao,et al.  Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. , 2008, Cancer research.

[24]  K. Hirata,et al.  Gastrointestinal , Hepatobiliary and Pancreatic Pathology Transcriptional Control of Tight Junction Proteins via a Protein Kinase C Signal Pathway in Human Telomerase Reverse Transcriptase-Transfected Human Pancreatic Duct Epithelial Cells , 2010 .

[25]  C. Hill,et al.  Smad4 Dependency Defines Two Classes of Transforming Growth Factor β (TGF-β) Target Genes and Distinguishes TGF-β-Induced Epithelial-Mesenchymal Transition from Its Antiproliferative and Migratory Responses , 2005, Molecular and Cellular Biology.

[26]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[27]  Zhan Hua,et al.  Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. , 2003, World journal of gastroenterology.

[28]  Margaret S. Ebert,et al.  Roles for MicroRNAs in Conferring Robustness to Biological Processes , 2012, Cell.

[29]  F. Motoi,et al.  Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells , 2003, Oncogene.

[30]  B. Shen,et al.  Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. , 2010, Biochemical and biophysical research communications.

[31]  A. Horii,et al.  Molecular pathology of pancreatic cancer , 2014, Pathology international.

[32]  J. Ju,et al.  Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer , 2013, Journal of Gastroenterology.

[33]  L. Lim,et al.  An Abundant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans , 2001, Science.

[34]  S. Jakowlew.  Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.

[35]  R. Hruban,et al.  Missense Mutations of MADH4 , 2004, Clinical Cancer Research.

[36]  T. Muniraj,et al.  Pancreatic cancer: a comprehensive review and update. , 2013, Disease-a-month : DM.

[37]  W. Han,et al.  The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression , 2013, PloS one.

[38]  C. Tudur-Smith,et al.  Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer , 2011, British Journal of Cancer.

[39]  Qiang Sun,et al.  Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway , 2012, Nucleic acids research.

[40]  Zhiming Wang,et al.  miR-301a Is a Candidate Oncogene that Targets the Homeobox Gene Gax in Human Hepatocellular Carcinoma , 2012, Digestive Diseases and Sciences.

[41]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[42]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[43]  Zhongxin Lu,et al.  miR‐301a as an NF‐κB activator in pancreatic cancer cells , 2011, The EMBO journal.

[44]  Masao Tanaka,et al.  The Characteristics of Disseminated Tumor Cells in Pancreatic Cancer: A Black Box Needs to Be Explored , 2005, Pancreatology.

[45]  T. Jin,et al.  MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression , 2014, Oncotarget.